Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).

e13558 Background: D is a pan-aurora kinases inhibitor also active against other kinases with oncogenic potential, such as TRKA, RET, FGFRs, ABL. D has been showed to be active against a wide range...